Printer Friendly

ROBERTS PHARMACEUTICAL RECEIVES IRISH APPROVAL FOR PROSTATE CANCER DRUG

ROBERTS PHARMACEUTICAL RECEIVES IRISH APPROVAL FOR PROSTATE CANCER DRUG
 EATONTOWN, N.J., Jan. 17 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) today announced that the Irish regulatory authorities have granted formal approval for Somagard(R) (deslorelin) for the treatment of prostate cancer.
 Roberts' U.K. subsidiary company, Monmouth Pharmaceuticals Ltd., will launch the drug in the near future. This will be Roberts' first new drug developed for cancer treatment. Somagard is in late stage development in the United States and other countries for prostate cancer and other clinical indications. Prostate cancer is one of the three most common causes of cancer in men next to skin cancer and lung cancer, according to statistics published by the National Cancer Institute. About 100,000 males in the United States develop prostate cancer annually.
 Roberts CEO and Chairman Dr. Robert A. Vukovich, commented, "Although the Republic of Ireland is a relatively small commercial market, it is an important member state of the European Economic Community and has high regulatory standards. Our plan is to next submit the Somagard dossier to another EEC member state followed by a common market filing in Brussels. This would result in regulatory approval throughout the EEC."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non- prescription pharmaceuticals in the United States and abroad.
 -0- 1/17/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:


CK-OS -- NY029 -- 0985 01/17/92 12:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 17, 1992
Words:289
Previous Article:ATLANFED BANCORP, INC., ANNOUNCES RESULTS
Next Article:CITIZENS-NATIONAL FUEL JOINT VENTURE FINALIZED
Topics:


Related Articles
MATRIX PHARMACEUTICAL RECEIVES APPROVALS FOR HUMAN CLINICAL TRIALS IN CANCER
ROBERTS PHARMACEUTICALS NOTIFIED OF AMATINE APPROVABILITY IN NEW ZEALAND
ROBERTS PHARMACEUTICAL REPORTS CLINICAL TRAIL RESULTS FOR NEW ENDOCRINOLOGY DRUG
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
/C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/
ROBERTS PHARMACEUTICAL TO ENTER A CLINICAL TRIAL CONTRACT ON NEW DRUG FOR PROSTATE CANCER
ROBERTS PHARMACEUTICAL CORPORATION LAUNCHES SUPPRELIN -- ROBERTS' FIRST NEW DRUG LAUNCH IN THE U.S.
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES UK APPROVAL FOR SOMAGARD
SONUS Pharmaceuticals Announces Favorable EchoGen(R) Prostate Cancer Clinical Trial Results
Zeneca Pharmaceuticals Receives FDA Approval for ZOLADEX in Combination Treatment Against Early Stages of Prostate Cancer

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters